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INTRODUCTION
Cytomegalovirus (CMV) is a common human pathogen
that persists after an initial episode as a latent infection pro-
ducing few clinical symptoms in healthy individuals [1].
However, during periods of immune suppression, for exam-
ple, after allogeneic stem cell transplantation (SCT) or in
individuals infected with human immunodeficiency virus
(HIV), CMV may reactivate, causing signiﬁcant morbidity
and mortality [2-5]. CMV primary infection or reactivation
can result in a variety of clinical symptoms including inter-
stitial pneumonitis, gasteroenteris, hepatitis, retinitis, and
bone marrow hypoplasia [2,6,7].
Antiviral drugs such as ganciclovir (GCV) have proven to
be effective in treating CMV infection but are associated
with signiﬁcant toxicity, which limits their use, particularly in
blood or marrow transplant recipients [8-11]. Preemptive
treatment with GCV has been used as a strategy to selec-
tively treat only those patients in whom CMV reactivation
occurs. This strategy relies on detection of CMV reactiva-
tion in blood, using sensitive detection methods such as pp65
antigenemia or plasma polymerase chain reaction (PCR) for
CMV DNA, and has been effective in reducing CMV disease
without causing neutropenia [8,9,12-14]. Both prophylactic
and preemptive antiviral strategies are, however, imperfect.
Aside from the myelosuppressive effects of GCV, long-term
prophylactic use of antiviral drugs may cause a delay in the
regeneration of CMV-specific cellular immunity and may
contribute to the onset of late-CMV disease [15]. Further-
more, the use of preemptive GCV treatment may not be suf-
ﬁcient to prevent CMV disease under high viral load [4].
The importance of the cellular immune response in
controlling CMV proliferation has been well documented in
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ABSTRACT
Cytomegalovirus (CMV) is a common herpes virus that can cause significant morbidity and mortality in immuno-
compromised individuals, particularly those undergoing allogeneic stem cell transplantation (SCT) for hematologi-
cal malignancies. Recent studies have examined the kinetics of CMV-specific CD8+ T-cell reconstitution after SCT
transplantation and have found virus-specific cytotoxic T-lymphocyte regeneration to be dependent on CMV sero-
logic status and CMV reactivation events. However, the reconstitution kinetics of CMV-specific CD4+ T-cells under
these same circumstances were not addressed. In this study, we used HLA class I peptide tetramer for CMV pp65
and cytokine flow cytometry to follow the reconstitution of both CD4+ and CD8+ CMV-specific T-cells after allo-
geneic SCT. We found that following SCT in which both donors and recipients are CMV seropositive, virus-specific
CD4+ T-helper cells show the same reconstitution kinetics as CD8+ cytotoxic T-cells. Following CMV reactivation,
a synchronous but temporary increase in both CD4+ and CD8+ CMV-specific lymphocytes occurs. The pattern
repeats itself after subsequent episodes of CMV reactivation. These data imply that both CD4+ and CD8+ lympho-
cytes are necessary for an efficient immune response to CMV and suggest that CD4+ and CD8+ CMV-specific T-cells
are required for the complete restoration of CMV immunity. These findings may have important implications in the
development of CMV-specific adoptive immunotherapy strategies.
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both healthy and immune-suppressed individuals. Although
primary effector activity is attributed to CD8+ T-cells
[6,16-18], there is an increasing appreciation of the role of
CD4+ T-helper (Th) cells in developing an effective and
lasting immune response. Th cells not only have direct
effector activity through production of cytokines such as
interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and
interleukin-2 (IL-2), but also are essential in initiating and
maintaining cytotoxic T-lymphocyte (CTL) function and
numbers [19]. Indeed, deﬁciency in Th under circumstances
of rapidly replicating viral infection may lead to CTL
exhaustion [20]. This correlation between CD4+ deﬁciency
and CMV reactivation has been demonstrated in other
immune suppression scenarios such as HIV-1 infection [21]
and solid organ transplantation [22]. In addition, the adop-
tive transfer of CMV-speciﬁc CD8+ T-cell clones to restore
CMV immunity after transplantation showed that persis-
tence of CTL cytolytic activity was correlated with the
recovery of CD4+ T-cell help [18,23].
Documentation of the regeneration of CMV-specific
CD8+ T-cells in allogeneic SCT using HLA class I peptide
tetramers has shown that reconstitution of CTLs is depen-
dent on the serologic status of the recipient and donor,
CMV reactivation after transplantation, and posttransplan-
tation treatment strategies (antiviral and graft-versus-host
disease [GVHD] treatment) [24-26]. However, the system-
atic monitoring of the CMV-speciﬁc CD4+ T-cell response
in SCT recipients has not been reported. In this study, we
have examined the kinetics of both CD4+ and CD8+ CMV-
specific immune restoration following allogeneic SCT to
quantitate and document the timing and nature of the spe-
ciﬁc CMV response. We have used HLA class I tetramers
for direct visualization of CTLs [27] combined with lym-




The subjects of this study were 38 consecutive patients
who underwent peripheral blood SCT using HLA-identical
sibling donors for treatment of hematological malignancies
at Westmead Hospital, Sydney, during the period of 1999
through 2001. Patient characteristics are summarized in
the Table.
Transplantation Regimens
Patients received preparative therapy for SCT using
either myeloablative (busulphan 1 mg/kg orally 4 times a day
on days –7 to –4 and cyclophosphamide 60 mg/kg intra-
venously [IV] daily on days –3 and –2 or cyclophosphamide
60 mg/kg IV daily on days –5 and –4 with total body irradia-
tion at 2 Gy twice daily on days –2, –1, and 0 [without lung
shielding]) or nonmyeloablative (fludarabine 30 mg/m2 IV
daily on days –6 to –2 with cyclophosphamide 60 mg/kg IV
daily on days –3 and –2) regimens. Unmanipulated peripheral
blood stem cell transplants, obtained by granulocyte colony-
stimulating factor mobilization of HLA-identical sibling
donors, were infused on day 0. Cyclosporin, 1.5 mg/kg IV
twice a day (BID) from day –1, and methotrexate, 15 mg/m2
on day 1 and 10 mg/m2 days +3, +5, and +11, were given as
prophylaxis against GVHD in myeloablative transplant recip-
ients; mycophenolate 1 g BID was substituted for methotrex-
ate in nonmyeloablative transplant recipients. Fluconazole,
bactrim, and valaciclovir (500 mg daily from day 0 to day 100)
were given as fungal, Pneumocystis carinii pneumonia, and her-
pes simplex infection prophylaxis, respectively.
Monitoring for CMV Infection
Recipient and donor CMV serology was assessed using
enzyme-linked immunosorbent assay for immunoglobulin
(Ig)M and IgG antibodies for CMV late antigens [30]. To
monitor the occurrence of CMV reactivation, peripheral
blood samples were collected weekly from day +21 post-
SCT. Plasma and leukocytes from these samples were used
for CMV PCR and immunoﬂuorescence detection of pp65
antigen, respectively, performed according to published
methods [31,32].
Treatment of CMV Reactivation
CMV reactivation in SCT recipients was defined as
2 successive positive plasma PCR results 1 week apart, or a
pp65 immunofluoresence test showing 5 or more positive
Patient Characteristics
Characteristic No. of Patients










Age, median (range), y 35 (17-56)
Underlying disease
Acute lymphoblastic leukemia 10
Chronic myelogenous leukemia 9
Acute myelogenous leukemia 9
Chronic lymphocytic leukemia 2
Mantle cell non-Hodgkin’s lymphoma 2
Renal cell carcinoma 2
Aplastic anemia 1





Matched unrelated donor 5
Matched miniallogeneic 15
CMV reactivation
Reactivation (PCR, pp65) 17
No reactivation 21
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cells per 2 × 105 cells. Reactivation was treated with GCV
5 mg/kg IV BID for 14 days.
Blood Samples
Ten milliliters of heparinized blood was collected from
SCT recipients before and at time points up to 180 days
after SCT for CMV-specific T-cell analyses. If possible,
blood was also obtained from the donor prior to SCT mobi-
lization. Peripheral blood mononuclear cells (PBMCs) were
isolated by Ficoll-Isopaque density gradient centrifugation.
If possible, samples were collected weekly from day 28 to
day 90 after SCT, then every 2 months thereafter.
Major Histocompatibility Complex Class I-pp65
Tetramer Staining
Soluble major histocompatibility complex (MHC)-
peptide HLA-A*0201-restricted tetramers NLVPMVATV
(lower matrix protein pp65, amino acids 495-503) conju-
gated to phycoerythrin (PE) (Beckman Coulter, Immu-
nomics Division, Marseille, France) were used to deter-
mine the frequency of CMV-specific CD8+ T-cells. A total
of 2 × 105 PBMCs were incubated for 30 minutes with tetra-
mer and CD8 antibody (clone Leu-2a conjugated to fluo-
rescein isothiocyanate [FITC]) (BD Biosciences, San Jose,
CA). Cells were washed, fixed in 0.5% paraformaldahyde/
phosphate-buffered saline (PBS), then analyzed by flow
cytometry on a FACSCalibur flow cytometer (BD Bio-
sciences). During analysis, CD8+ T-cells were defined as
CD8+ events with low-to-medium forward light scatter
(FSC) and low side scatter (SSC).
CFC Assay
Frequencies of CMV-specific CD4+ and CD8+ T-cells
were analyzed by production of cytokines in response to
antigenic stimulation as previously reported [28,33]. Isolated
PBMCs from healthy stem cell donors and allogeneic SCT
recipients were stimulated with a polyvalent CMV antigen
and analyzed for the production of the cytokines IFN-γ, IL-2,
and TNF-α; 2 × 106 cells from fresh or cryopreserved
(rested overnight after thawing) PBMCs were incubated for
6 hours at 37°C in 5% CO2 in air in the presence of either
70 µL/mL of CMV viral lysate, 70 µL/mL negative control
antigen (BioWhittaker Inc, Walkersville, MD), or 25 ng/mL
phorbol myristate acetate and 1 µg/mL ionomycin (Sigma,
St. Louis, MO). After 1 hour, 10 µg/mL brefeldin A (Sigma)
was added and the cells were incubated for a further
5 hours. Cells were centrifuged and resuspended in 0.02%
EDTA-PBS and incubated for 15 minutes at 37°C. Cells
were centrifuged and washed in cold PBS, then ﬁxed in 4%
paraformaldahyde at 37°C for 5 minutes. The directly con-
jugated monoclonal antibodies CD69 PE, CD8-peridinin
chlorophyll protein (PerCP), and CD4-allophycocyanin
(APC) (Becton Dickinson, San Jose, CA) were used to stain
for cell surface antigens. Cells were washed and permeabi-
lized with IC-Perm permeabilization buffer (Biosource,
Camarillo, CA). Subsequently, cells were washed and then
incubated with FITC-conjugated intracellular cytokine anti-
bodies IL-2, IFN-γ, and TNF-α (BD Biosciences). Afterward,
cells were washed, resuspended in 1% paraformaldahyde in
PBS plus 1% bovine serum albumin, and analyzed by ﬂow
cytometry using a FACSCalibur (Becton Dickinson)
equipped with a 488-nm argon and 635-nm red diode laser.
Data files containing >10,000 events positive for CD4 or
CD8 PerCP fluorescence within a lymphocyte gate were
analyzed. CD4+ and CD8+ cells were double-gated by gating
on events with low-to-medium FSC and low SSC and then
on CD4+ and CD8+ events. This population was then ana-
lyzed for the CD69 activation marker and cytokine produc-
tion. The frequency of the control antigen was subtracted
from the frequency of the CMV antigen population to
determine CMV-speciﬁc T-cell frequency.
Determination of Absolute CMV-Specific T-Cells
The absolute number of CMV-speciﬁc CD4+ and CD8+
lymphocytes per milliliter was calculated using the absolute
lymphocyte count, obtained during routine blood counts,
using a previously published formula [33]:
Absolute CMV-speciﬁc T-cells (cells/µL) = (%CD4/CD8
gated lymphocytes) × (%CMV-speciﬁc CD4/CD8 T-cells).
Statistical Methods
The following factors were analyzed in a univariate
analysis for their effect on CMV-specific CD8+ or CD4+
reconstitution: serologic status of donor, serologic status of
recipient, recipient/donor serologic status combination, and
episode of CMV reactivation. For nonparametric statistical
analyses, Wilcoxon test and Spearman rank correlation were
used. P values <.05 were considered signiﬁcant.
RESULTS
Patient Population
A total of 38 consecutive HLA-identical sibling SCT
patients were evaluated for CMV-speciﬁc lymphocyte recon-
stitution (Table). These patients were examined using the
CMV pp65 tetramer HLA-A*0201 495-503 (n = 24) or by
evaluating cytokine production after CMV antigenic stimu-
lation (n = 24) or using both methods (n = 9) (Figure 1).
Validation of Detection Methods
We first validated analytical methods by comparing
healthy CMV seropositive and seronegative donors using
both tetramer (Figure 2A) and CFC (Figures 2B and 2C).
Analysis of CMV seropositive (n = 6) and seronegative (n = 6)
donor samples by NLV-tetramer showed speciﬁc staining of
tetramer-positive CD8+ T-cells only in those individuals
who were CMV seropositive. CMV seropositive samples had
a median tetramer-positive lymphocyte value of 0.79%
(range, 0.27%-1.74%), whereas CMV seronegative samples
had a median value of 0.04% (range, 0%-0.1%) (P = .02)
(Figure 3A). Cells from individuals who were not HLA-A*0201
positive did not stain with the tetramer (data not shown).
Stimulating PBMCs with CMV antigen resulted in
more specific and sensitive quantitation of CMV-specific
CD4+ and CD8+ lymphocytes in cells from healthy CMV-
seropositive (n = 6) individuals than in cells from CMV-
seronegative individuals (n = 6); only seropositive donors
produced signiﬁcant quantities of IFN-γ and TNF-α com-
pared to seronegative donors (Figure 3B). CMV-seropositive
individuals had a statistically signiﬁcant higher frequency of
CD4+ lymphocytes producing IFN-γ and TNF-α (P = .04
and P = .04, respectively) and a higher frequency of CD8+
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lymphocytes producing IFN-γ (P = .04) than did CMV-
seronegative individuals. In samples from seropositive indi-
viduals, CD4+ T-cells were detected at a median frequency
of 0.31% ± 0.32% and 0.32% ± 0.25% for IFN-γ and
TNF-α, respectively, compared to 0.06% ± 0.04% and
0.07% ± 0.03%, respectively, in seronegative samples (Fig-
ure 3B). CD8+ T-cells were detected at a frequency of
0.21% ± 0.17% and 0.16% ± 0.25% for IFN-γ and TNF-α,
respectively, in seropositive patients compared to 0.04% ±
0.04% and 0.05% ± 0.08%, respectively, in seronegative
patients (Figure 3B). Neither seropositive nor seronegative
lymphocytes produced IL-2 after CMV stimulation (data
not shown).
Serologic Status
For evaluation of CMV-specific T-cell reconstitution
after allogeneic stem cell transplantation, PBMCs were col-
lected weekly from day 28 post-SCT. Patient PBMCs were
analyzed by HLA-A*0201 495-503 tetramer binding and/or
by cytokine production after exposure to CMV antigen.
Figure 4 shows the reconstitution data of CD4+ and CD8+
CMV-speciﬁc T-cells after allogeneic SCT in the 9 patients
analyzed by both methods (Figure 1). Kinetics of both CD4+
and CD8+ reconstitution appeared to be dependent on dif-
ferent transplantation variables including CMV serologic
status of the patient and donor and CMV reactivation post-
transplantation.
To conﬁrm that serologic status was a signiﬁcant factor
in CMV-specific T-cell reconstitution, we distributed
patients into 3 groups based on CMV serologic status. In
group I (see Figure 1 for patient group description), both
patient and donor were CMV seropositive (n = 13). In group
II, the patient was seropositive and the donor seronegative
(n = 6). In group III, the patient was seronegative and the
donor was seropositive (n = 4). The median number of tests
analyzed per patient was 7 (range, 4-15). Analysis of the
median peak CMV-specific T-cell subset number during
posttransplantation recovery showed that CMV-reconstitution
was dependent on CMV serologic status of both patient and
donor. According to results of analysis of peak tetramer
CMV-speciﬁc T-cell recovery, group I had a higher percent-
age (P = .004) of CMV-specific CD8+ T-cells (median,
3.7%; range, 0.74%-18.1%) than did group II (median,
0.20%; range 0%-0.28%) and a signiﬁcantly higher percent-
age (P = .004) than did group III (median, 0.15%; range
0%-0.44%) (Figure 5A). Similarly, peak absolute cell num-
ber in group I was signiﬁcantly higher than in group II and
III (P = .01 and P = .01, respectively). The absolute number
of tetramer-positive CD8+ cells for group I was a median of
23 (range, 0.4-501) cells/µL compared to a median in group
II of 1.3 (range, 0-6.1) cells/µL and in group III of 2 (range,
0-4.3) cells/µL (Figure 5B).
Figure 1. Patient CMV-speciﬁc T-cell detection method distribution and groupings. A total of 38 patients were analyzed for CMV-speciﬁc CD4+
and CD8+ T-cells by either HLA-A*0201 pp65495-503 (NLVPMVATV)-speciﬁc tetramer or by CFC assay to determine whether CMV serology (A)
or CMV reactivation (B) posttransplantation inﬂuence recovery of CMV-speciﬁc cellular immunity. P indicates patient; D, donor.
Figure 2. Detection of CMV-specific CD4+ and CD8+ T-cells by
tetramer or by CFC. The frequency of CD8+ CMV-speciﬁc T-cells can
be measured by staining with tetramer-PE and CD8+ FITC in a
healthy HLA-A*0201 positive, CMV seropositive donor (A). CD4+
CMV-speciﬁc T-cells can be determined by analyzing for cells (gated
on CD4+ lymphocytes) that produce IFN-γ (B) or TNF-α (C) and
express the T-cell activation antigen CD69.
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Analysis of CD8+ CTLs using CFC showed a similar
trend, although the observed frequency of CTLs was much
lower; the median peak CMV-specific CD8+ T-cell fre-
quency in group I (n = 17) was 0.48% (range, 0%-2.39%)
compared with group II (n = 4), in which the median peak
was 0.01% (range, 0%-0.87%) (P = .08). Comparison of
group I with group III (n = 3) showed a statistically signiﬁ-
cant difference (P = .0003), in which the median peak fre-
quency of CTLs in CMV seronegative recipients who
received a seropositive graft was 0.0% (range, 0%-0.12%)
(Figure 5C).
CD4+ T-cells have been shown to be essential in the
development and expansion of antigen-speciﬁc CD8+ CTLs
through dendritic cell stimulation [34,35] and may be
instrumental in controlling CMV proliferation. For evalua-
tion of the role that CD4+ T-cells play in CMV defense
after transplantation, CD4+ cells were monitored simultane-
ously with CD8+ T-cells. As observed for CD8+ T-cells,
CMV-serologic status of patient and donor played a signiﬁ-
cant role in CMV-speciﬁc CD4+ reconstitution in transplant
recipients. Patients in group I (n = 17) had a median peak
CMV-speciﬁc CD4+ percentage of 0.68% (range, 0%-3.9%),
which was signiﬁcantly higher than the percentage in group
II (n = 4), which had a median value of 0.10% (range, 0%-
0.21%), and group III (n = 3), with a median of 0.11%
(range, 0%- 0.23%) (P = .002 and P =.002, respectively)
(Figure 6). There were no statistical differences between
groups II and III. These ﬁndings support data pointing to
the importance of CMV serologic status as a contributing
factor to CMV-specific immune reconstitution after allo-
geneic SCT or bone marrow transplantation [24,25].
CMV Reactivation
Observations have been made regarding the cause-and-
effect relationship between viral replication and the expansion
of virus-speciﬁc CTLs [24,25,36]. Figure 4 shows increases
in CMV-speciﬁc cells occurring shortly after the detection
of CMV reactivation by PCR or immunoﬂuorescence. For
Figure 3. Validation of detection methods in healthy individuals. Detection of CMV-speciﬁc CD4+ and CD8+ T-cells in healthy seropositive () or
seronegative () individuals was performed using either tetramer (A) or cytokine ﬂow cytometry staining of cells for production of either IFN-γ or
TNF-α after antigenic stimulation for either CD4+ or CD8+ T-cells (B). Asterisk indicates statistical signiﬁcance of <.05.
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examination of whether this trend was followed by increases
in both CD8+ and CD4+ lymphocytes in allogeneic SCT
patients, samples were examined by tetramer and CFC. To
examine the CD8+ T-cell response using tetramer, patients
were divided into 2 groups. Patients that had episodes of
CMV reactivation were placed in group IV (n = 11) and
compared with patients placed in group V (n = 13), who did
not have reactivation. Reactivation in group IV occurred at
a median of 33 days (range, 20-46 days) after transplanta-
tion and was followed by a CD8+ T-cell expansion peak on
median day 56 (range, day 28-63). Group IV showed a
signiﬁcantly higher percentage (P = .007) of CMV-speciﬁc
CD8+ T-cell reconstitution associated with CMV reactiva-
tion events than did group V. Tetramer staining of samples
from individuals with episodes of CMV reactivation
showed massive expansion of CMV-specific CD8+ T-cells,
with up to 18.1% of all CD8+ cells recognizing pp65.
Median peak CMV-speciﬁc CD8+ T-cell percentages were
higher in group IV (P = .001), with a median of 4.9%
(range, 0.74%-18.1%), compared to group V, with a median
of 0.29% (range, 0%-0.8%) CD8+ T-cells (Figure 7A). Calcu-
lation of the absolute CMV-specific CD8+ T-cells after
transplantation indicated that the number of T-cells recog-
nizing CMV was much higher in those individuals devel-
oping CMV reactivation; group IV had a median absolute
cell number of 27 (range, 0.4-501) cells/µL compared to
group V, with a median of 0.3 (range, 0-23) cells/µL (P = .1)
(Figure 7B).
Accordingly, we examined the CD4+ response to evalu-
ate the effect of CMV reactivation on immune reconstitution.
Using the CFC test, we compared expansion of CMV-speciﬁc
CD4+ T-cells in group IV (n = 13) with that in group V (n =
11). CMV reactivation was associated with a signiﬁcant dif-
ference between the 2 groups in peak CMV-speciﬁc CD4+
T-cells posttransplantation (P = .009). The median peak
value in group IV was 0.85% (range, 0%-3.89%), whereas
the median for group V was 0.18% (range, 0%-0.77%) (Fig-
ure 8). Furthermore, expansion peaks of both CD4+ and
Figure 4. Analysis of CD4+ and CD8+ CMV-specific T-cells using CFC and tetramer staining methods in 9 allogeneic SCT recipients. The
absolute number of CD4+ CMV-speciﬁc T-cells (H17009) was measured by CFC and compared to the absolute number of CD8+ CMV-speciﬁc T-cells
(), which were assessed by tetramer staining. The CMV recipient/donor serologic status of these 9 SCT recipients (patients 16 through 24) (recip-
ient seropositive/donor seropositive, +/+; recipient seropositive/donor seronegative, +/–; or recipient seronegativ/donor seropositive, –/+) is indi-
cated in the corner of each graph. Arrows indicate incidence of CMV reactivation as determined by CMV PCR and antigenemia. Inset bars for each
patient indicate treatment with GCV (solid gray bar) in response to CMV reactivation and/or disease and steroid treatment (hashed bar) for GVHD.
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CD8+ lymphocytes appeared to be associated with episodes
of CMV reactivation and followed the same pattern of
expansion as seen in Figure 4. Several recipients (patients 16
through 20) who were analyzed for both CD4+ and CD8+
T-cells concurrently showed marked increases in CMV-
specific CD8+ frequency and corresponding CD4+ expan-
sion after CMV reactivation. The CMV-specific response
declined after the initial reactivation period, most likely
because of decreasing antigen levels caused by preemptive
GCV and control of viral proliferation by elements of the
cellular immune response.
DISCUSSION
The impairment of the cellular immune response in
allogeneic SCT patients may result in the reactivation of
viral pathogens, such as CMV, which can cause signiﬁcant
morbidity and mortality. CMV reactivation during this
period of immune suppression has been primarily attributed
to the temporary but severe deficiency of CD8+ CTLs
[15,17,18]. Under these circumstances, the regeneration of
functional CMV-speciﬁc immunity is essential for limiting
problems associated with CMV reactivation. Recent studies
have used HLA class I tetramers that bind to epitope-speciﬁc
Figure 5. Tetramer or CFC detection of the effect of CMV serologic status on CD8+ CMV-speciﬁc T-cell recovery in patients who received an
allogeneic stem cell graft. Data points indicate the peak frequency or absolute cell number during posttransplantation analysis. Stem cell graft recipi-
ents were stratiﬁed into groups in which both the recipient and donor were seropositive (), the recipient was seropositive and the donor was
seronegative (), or the recipient was seronegative and the donor was seropositive (). The abundance of CMV-speciﬁc CD8+ T-cells was analyzed
by tetramer and reported as a percentage (A) or as an absolute cell number (B). CD8+ T-cells were also analyzed for cytokine production (IFN-γ) in
response to CMV antigen stimulation (C). Asterisk indicates statistical signiﬁcance of <.05.
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T-cell receptors recognizing CMV pp65 to evaluate the
kinetics of the CD8+ CTL response after transplantation
[24,25]. There have been few observations, however, regard-
ing the kinetics of CMV-specific CD4+ T-cells after allo-
geneic SCT. In the present study, we have documented the
regeneration of both CD4+ and CD8+ CMV-speciﬁc T-cells
in this setting.
Validation of different methods of CMV-speciﬁc T-cell
detection was essential in comparing lymphocyte reconstitu-
tion. We found both NLV-tetramer staining and CFC to be
speciﬁc and sensitive for measuring CMV-speciﬁc T-cells in
healthy individuals. We found a wide range in the frequency of
CMV-speciﬁc CD8+ T-cells, ranging from 0.27% to 1.74% of
all CD8+ T-cells in the peripheral blood of latently infected
healthy individuals. These analysis results differed signifi-
cantly from those of peripheral blood from healthy seronega-
tive individuals, in whom these cells were absent. Similarly,
using CFC, we were able to detect a higher frequency of
CMV-specific CD4+ and CD8+ T-cells in seropositive
patients than in seronegative patients. Earlier observations
using this method reported similar values for latently infected
healthy individuals [28,29].
Reconstitution kinetics of CD4+ Th cells have been of
particular interest in the context of HIV infection and
highly active antiretroviral therapy (HAART) [5] but have
been not been closely examined in SCT. We therefore
sought to examine CD4+ restoration and use tetramer stain-
ing and CFC analysis to compare it to CD8+ regeneration.
In accordance with other published reports, we found a dra-
matic increase in CMV-speciﬁc CD4+ and CD8+ T-cells in
some patients following allogeneic SCT. Tetramer analysis
results indicated that CD8+ pp65-speciﬁc cells reached fre-
quencies as high as 18% of all CD8+ T-cells. These results
are comparable to those observed by Cwynarski et al. and
Gratama et al. demonstrating extensive CMV-speciﬁc CD8+
expansion (up to 21% of CD8+ T-cells) in allogeneic SCT
recipients [24,25]. Furthermore, treatment strategy of the
patient cohort (eg, myeloablative versus nonmyeloablative)
did not appear to influence CMV reconstitution with
Figure 6. Effect of CMV serologic status on CD4+ CMV-speciﬁc T-cell
recovery in patients who received an allogeneic stem cell graft. Data
points indicate the peak frequency of CMV-specific CD4+ T-cells
during posttransplantation analysis. Stem cell graft recipients were
stratified into groups in which both the recipient and donor were
seropositive (), the recipient was seropositive and the donor was
seronegative (), or the recipient was seronegative and the donor was
seropositive (). CD4+ CMV-speciﬁc T-cells were detected by measur-
ing for IFN-γ after stimulation with CMV antigen. Asterisk indicates
statistical signiﬁcance of <.05.
Figure 7. Effect of CMV reactivation on CD8+ CMV-speciﬁc T-cell recovery after allogeneic SCT. Staining with tetramer was used to compare the
frequency (A) and the absolute number (B) of CMV-speciﬁc CD8+ T-cells in patients who had CMV reactivation () (as measured by PCR and pp65
antigenemia) following allogeneic SCT with those in patients who did not have CMV reactivation (). Asterisk indicates statistical signiﬁcance of <.05.
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respect to serologic status. Our data show that CD4+ T-cells
demonstrated a similar reconstitution pattern; in 1 patient,
CD4+ T-cells expanded to 3.9% of all CD4+ T-cells. There
was a strong correlation between CD4+ and CD8+ CMV-
speciﬁc T-cell regeneration.
Donor and recipient CMV serology has been correlated
with cellular immune reconstitution after SCT [37-39] and
directly related to the reconstitution of CMV-speciﬁc CTLs
[15,24,25,40,41]. It has been suggested that CMV-specific
CD8+ T-cells regenerate faster in CMV seropositive
patients who receive grafts from CMV seropositive donors
[15,42,43]. Our data support these observations and extend
them to CMV-specific CD4+ cells, which also appear to
reconstitute as a function of CMV serology. Our data also
suggest that recovery and sustained function of specific
CD8+ cell–mediated cytotoxicity after transplantation may
require concurrent expansion and activation of virus-speciﬁc
Th cells. CD4+ T-cells are necessary for the regulation of
cell-mediated immunity, in particular the promotion of
cytotoxic T-cell activity through Th1 cytokine elaboration
[44-46] and activation of antigen-presenting cells [47]. This
hypothesis has been supported by clinical observations
involving adoptively transferred CMV-specific clones [18].
In these experiments, CMV viremia was efficiently pre-
vented following T-cell clone transfusion; however, the
long-term persistence of these cells required the endoge-
nous recovery of CMV-specific CD4+ Th cells. These
results and other evidence [22] support the hypothesis that
CD4+ T-cells are necessary for maintaining an efﬁcient and
long-term immune response to prevent CMV disease.
Our observations suggest that the increased numbers of
both CD4+ (presumably Th) and CD8+ CMV-speciﬁc T-cells
documented after transplantation in seropositive donor/
recipient pairs may be due to cell expansion induced by CMV
reactivation (see Figure 4, patients 16 and 17). Cwynarski et al.
presented ﬁndings suggesting that reconstitution of CMV-
speciﬁc CD8+ T-cell activity is promoted by proliferation of
endogenous CMV in seropositive patients [24]. The change
from latent infection to active proliferation produces a strong
antigenic stimulation that may drive CMV-specific T-cell
expansion. Our data support these findings. We identified
sharp rises in CD4+ and CD8+ CMV-speciﬁc T-cell frequen-
cies occurring soon after CMV reactivation in recipients
posttransplantation. This trend was generally followed by a
decrease in virus-speciﬁc T-cell number with the administra-
tion of GCV or other antiviral drugs. Only 1 of our patients
developed CMV disease (CMV colitis), and we were there-
fore not able to determine if CD4+ and CD8+ T-cell levels
were solely responsible for limiting CMV disease.
The use of tetramers and CFC to detect and quantitate
CMV-speciﬁc CD4+ Th and CD8+ cytotoxic T-cell recovery
after transplantation represents another tool for the assess-
ment of CMV reactivation in immunocompromised hosts.
Together with CMV detection techniques, these analytical
techniques may assist in tailoring CMV therapeutic strate-
gies to limit antiviral drug use and also may facilitate further
investigation of current CMV and GVHD treatment strate-
gies, in particular the effect of GCV and corticosteriod
treatment on CMV-specific Th cells. Detailed analysis of
the requirements of virus-speciﬁc Th cells and CTLs in the
context of allogeneic SCT will be essential in the develop-
ment of adoptive immunotherapy strategies that employ
both Th and CTL virus-specific cells to restore CMV
immunity shortly after allogeneic transplantation.
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